วก. จะเลิกเสือก @WikromP

SG is a highly effective ADCs, and when used adequately, it saves lives. This includes careful management of toxicities, with prophylaxis when indicated. In this article we review the data & provide RW perspectives on the management of toxicities with SG. academic.oup.com/oncolo/advance…

Molecular and Therapeutic Landscape of Non-Clear Cell Renal Cell Carcinoma: 🧬🧬🧬Diverse subtypes, unique genetics, unpredictable responses. @NatRevUrol @OncoAlert @kidneycan @IKCCorg @kidneycancer @MehrazinMD rdcu.be/ewjT8

keyboard_arrow_left Previous keyboard_arrow_right Next

🚨 Just out in @JTOonline! A must-read review from the @IASLC Communications Committee: 50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic jto.org/article/S1556-… 🧭 A fast-track tour in #LungCancer, from staging to immunotherapy. Perfect to breathe in the past before sprinting into the future! 🫁 Congrats to @ADesaiMD and all the team! 👏🏼 @OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM @gecp_org @Lung_Cancers @LungCancerRx @LungCancerEu

Beyond excited to share our latest collaborative work! Immense pride in congratulating our rising stars @hatice_bolek and @coskunyazgann on this excellent work! Huge thanks to all coauthors @yekeduz_emre @Silke_Gillessen @DrRanaMcKay , and Marina for incredible contributions and unwavering support! #ProstateCancer #Oncology #OncoAlert #ESMO @OncoAlert @myESMO @ESMO_Open @APCCC_Lugano @DanaFarber @AnkaraUni

1/2 🫁 Stage III - Unresectable NSCLC 🫁 🫁 Summary of treatment regimen as of October, 2024 🫁 🌟 @EORTC : Consensual definition of stage III NSCLC resectability 🌟 #WCLC23 abst #OA06.05

From backstage to the spotlight: γδT cells in cancer dlvr.it/TFQ77l

💊Third line and beyond in mCRC👇 ✅Trials and mOS @myESMO @OncoAlert #cancer #oncology #MedX

How To Choose a Good Scientific Problem (1/3) @MolecularCell #PhD #PhDlife #academics #AcademicChatter #AcademicTwitter #Postdocs #Research #Science

💫🌟Early-Onset Cancers: Unraveling Biological Causes and Clinical Implications🌟💫 @OncoAlert 🔷 Understanding Early-Onset Cancers Over the past three decades, the incidence of early-onset (EO) cancers—those diagnosed in individuals under the age of 50—has been rapidly rising. While EO cancers traditionally affected older adults, recent epidemiological data highlight a disturbing increase in diagnoses among adolescents and young adults, notably in cancers like colorectal cancer (CRC) and breast cancer (BC). 🔷 Key Points • Rising Incidence: ➤ The incidence of EO cancers globally increased by 80% from 1990 to 2019, especially in gastrointestinal, colorectal, and breast cancers. ➤ Notably, EO-CRC is projected to account for one-third of all CRC cases by 2030. • Impact of the Exposome: ➤ The rise in EO cancers may be linked to changes in environmental exposures, including diet Westernization, increased consumption of processed foods, exposure to carcinogens, and shifts in lifestyle factors like physical inactivity and obesity. ➤ Environmental pollutants, such as PM2.5 and microplastics, are also suspected contributors. • Challenges in Screening: ➤ Current screening protocols may not be well-suited to EO cancers, especially in CRC, where tumors may develop faster in younger populations. ➤ Innovations like circulating tumor DNA (ctDNA) monitoring could be key in developing more effective, non-invasive screening strategies for early detection. 🔷 Hypotheses on EO Cancer Evolution • Biological Peculiarities: ➤ EO cancers may follow different biological pathways compared to late-onset cancers. There is growing interest in understanding if EO tumors exhibit distinct molecular profiles that affect treatment responses, potentially requiring tailored therapeutic approaches. • Multi-Omics Integration: ➤ Comprehensive multi-omics profiling is essential to uncover the genetic, epigenetic, and transcriptomic features unique to EO cancers. International collaborations and biobanks focusing on EO cancer samples are critical to advancing this research. 🔷 Conclusion The surge in early-onset cancers presents an urgent public health challenge. By integrating epidemiological, environmental, and molecular data, we can develop a deeper understanding of the biology driving these cancers. This approach, referred to as the EO-cancer integrome, could ultimately lead to more effective prevention, diagnosis, and treatment strategies. #EarlyOnsetCancer #CancerResearch #Oncology #PrecisionMedicine #ColorectalCancer #BreastCancer #Exposome #PublicHealth #MultiOmics cell.com/cell-reports-m…

keyboard_arrow_left Previous keyboard_arrow_right Next

🟠Trials in advanced pancreatic cancer👇 ❌Failure and ✅Success @myESMO @OncoAlert #cancer #oncology #pancreatic #MedX

🛡️ Cancer cells use "3 Cs" to evade the immune system: 1️⃣ Camouflage: Hiding from immune detection. 2️⃣ Coercion: Disrupting immune function. 3️⃣ Cytoprotection: Shielding from immune attacks. Blocking these mechanisms enhances immunotherapy and restores anticancer immune surveillance. #Cancer #Oncology @OncoAlert @Cancer_Cell doi.org/10.1016/j.ccel…

ชอบอันนี้ ✌🏻 ทำ ‘ฝัน’ ให้เป็น ‘จริง’ มีวินัย สม่ำเสมอ เรียนรู้ ลงมือทำ ด้วยปัญญา

Types of paralysis: #neurotip #stroke

After a spinal shock: when do reflexes return?! #neurotip #neurotrauma

Online Now: Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion dlvr.it/TFFc4P

The triplet of inavolisib (PI3Kinh) + fulvestrant + palbo is now approved for pts with PIK3CA-mut HR+/HER2- BC ❓When do you want to use this? ➡️ Patients with rapidly recurrent PIK3CA mutant disease (ie with recurrence on or shortly after adjuvant ET) fda.gov/drugs/resource…

Lateral medullary syndrome by @neudrawlogy #neurotip #stroke

APCCC 2024 focuses on key challenges in advanced #ProstateCancer management. Highlights include new consensus! Congratulations @Silke_Gillessen @AOmlin for extraordinary efforts! Happy to take a part alongside the great panel members! @EUplatinum @APCCC_Lugano @myESMO @Uroweb @OncoAlert sciencedirect.com/science/articl…

NEW content online! Compressive stresses in cancer: characterization and implications for tumour progression and treatment go.nature.com/4eXaIRD

#Inavolisib now @US_FDA approved based off #INAVO120: Ph III, Inavolisib (iPI3Ka) + Fulv + Palbo vs Palbo/Fulvestrant HR+ metastatic breast cancer: - OS immature (favoring Inavo HR 0.64) - PFS 15.0 vs 7.3mos (HR 0.43) - AEs: >50% hyperglycemia & stomatitis #bcsm #OncTwitter

keyboard_arrow_left Previous keyboard_arrow_right Next